Scientific foundations-lower facial contouring with botulinum toxin type a

Journal of Craniofacial Surgery

Volumn 19, Issue 6, 2008, Pages 1613-1617

  Tartaro, Gianpaolo ^a   Rauso, Raffaele ^a,b   Santagata, Mario ^a   Santillo, Vincenzo ^a   Itro, Angelo ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Corso Aldo Moro ^*  (Italy)

Author keywords

Botulinum toxin type A; Lower facial contouring; Masseteric muscle hypertrophy

Indexed keywords

BOTULINUM TOXIN A; CYCLOBENZAPRINE; THIOCOLCHICOSIDE; AMITRIPTYLINE; ANTIMITOTIC AGENT; CENTRAL MUSCLE RELAXANT; COLCHICINE; COLCHICOSIDE; DRUG DERIVATIVE; MUSCLE RELAXANT AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; ELECTROMYOGRAPHY; EVENING DOSAGE; FACE ASYMMETRY; FEMALE; HUMAN; HYPEROSTOSIS; MALE; MASSETERIC MUSCLE HYPERTROPHY; MUSCLE HYPERTROPHY; NON INVASIVE PROCEDURE; PATIENT SATISFACTION; PRIORITY JOURNAL; TREATMENT OUTCOME; DRUG EFFECT; FOLLOW UP; HYPERTROPHY; INTRAMUSCULAR DRUG ADMINISTRATION; MASSETER MUSCLE; MIDDLE AGED; MUSCLE CONTRACTION; PATHOLOGY; PROSPECTIVE STUDY;

AMITRIPTYLINE; ANTIMITOTIC AGENTS; BOTULINUM TOXIN TYPE A; COLCHICINE; ELECTROMYOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTROPHY; INJECTIONS, INTRAMUSCULAR; MALE; MASSETER MUSCLE; MIDDLE AGED; MUSCLE CONTRACTION; MUSCLE RELAXANTS, CENTRAL; NEUROMUSCULAR AGENTS; PATIENT SATISFACTION; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 63249095588     PISSN: 10492275     EISSN: None     Source Type: Journal    
DOI: 10.1097/SCS.0b013e31818973c8     Document Type: Article

References (28)

1. Jost WH. Other indications of Botulinum toxin therapy. Eur J Neur 2006;13:65-69
2. Rocenvic R. Masseter muscle hypertrophy. Aetiology and therapy. J Maxillofac Surg 1986;14:344
3. Moore AP, Wood GD. The medical management of masseteric hypertrophy with botulinum toxin type A. Br J Oral Maxillofac Surg 1994;32:26
4. Smyth AG. Botulinum toxin treatment of bilateral masseteric hypertrophy. Br J Oral Maxillofac Surg 1994;32:29
5. Mandel L, Tharakan M. Treatment of unilateral masseteric hypertrophy with botulinum toxin: case report. J Oral Maxillofac Surg 1999;57:1017
6. Newton JP, Cowpe JG, McClure IJ, et al. Masseteric hypertrophy: preliminary report. Br J Oral Maxillofac Surg 1999;37:405
7. National Institutes of Health (NIH). Clinical use of botulinum toxin. National Institutes of Health Consensus Development Conference Statement, November 12-14, 1990. Arch Neurol 1991;48:1294
8. Rijsdijk BA, van ES RJ, Zonneveld FW, et al. De toepassing van botuline A toxine bij cosmetisch storende M-masseterhypertrofie. Ned Tijdschr Geneeskd 1998;142:529
9. Finn S, Ryan P, Sleeman D. The medical management of masseteric hypertrophy with botulinum toxin. J Ir Dent Assoc 2000;46:84
10. To EW, Ahuja AT, Ho WS, et al. A prospective study of the effect of botulinum toxin A on masseteric muscle hypertrophy with ultrasonographic and electromyographic measurement. Br J Plast Surg 2001;54:197
11. von Lindern JJ, Niederhagen B, Appel T, et al. Type A botulinum toxin for the treatment of hypertrophy of the masseter and temporal muscles: an alternative treatment. Plast Reconstr Surg 2001;107:327
12. Converse JM. Masseter Muscle Hypertrophy: Unpublished Case, 1951. In: Reconstructive Plastic Surgery, 2nd ed. Philadelphia: Saunders, 1977.
13. Whitaker LA. The prominent mandibular angle; Preoperative management operative technique, and results in 42 patients (Discussion). Plast Reconstr Surg 1989;83:279
14. Baek SM. Aesthetic contouring of the facial skeleton. Probl Plast Reconstr Surg 1991;1:673
15. Hong JU, Choi J, Baek SM. Study on resected area and masticatory muscle's histopatology and radiologic changes after Gato's mandibular osteotomy. Korea Soc Plast Surg 1994;21:857
16. Yang DB, Park CG. Mandibular contouring surgery for purely aesthetic reasons. Aesthetic Plast Surg 1991;15:53
17. von Lindern JJ, Niederhagen B, Appel T, et al. Type A botulinum toxin for the treatment of hypertrophy of the masseter and temporal muscle: an alternative treatment. Plast Reconstr Surg 2001;107:327
18. Borodic GE, Cozzolino D, Ferrante R, et al. Innervation zone of orbicularis oculi muscle and implications for botulinum A toxin therapy. Ophthal Plast Reconstr Surg 1991;7:54-60
19. Simpson LL. Peripheral actions of the botulinum toxins. In: Simpson LL, ed. Botulinum neurotoxin and tetanus toxin. San Diego, CA: Academic Press, 1989:153-178
20. Pamphlett R. Early terminal and nodal sprouting of motor axons after botulinum toxin. J Neurol Sci 1989;92:181-192
21. Schwartz KS, Jankovic J. Predicting the response to botulinum toxin injections for the treatment of cervical dystonia. Neurology 1990;40:382
22. Dressler D. Botulinum toxin therapy failure: causes, evaluation procedures and management strategies. Eur J Neurol 1997;4:S67-S70
23. Dressler D. Clinical presentation and management of antibodyinduced failure in hemifacial spasm. J Neurol 2004;19:S92-S100
24. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology 1995;45:1743-1746
25. Lee SK. Antibody-induced failure of botulinum toxin type A therapy in a patient with masseteric hypertrophy. Dermatol Surg 2007;33:S105-S110
26. Kim NH, Chung JH, Park RH, et al. The use of botulinum toxin type A in aesthetic mandibular contouring. Plast Reconstr Surg 2005;115:919-930
27. Park MY, Ahn KY, Jung DS. Botulinum toxin type A treatment for contouring of the lower face. Dermatol Surg 2003;29:477-483; discussion 483
28. Castro WH, Gomez RS, Oliveira J, et al. Botulinum toxin type A in the management of masseter muscle hypertrophy. J Oral Maxillofac Surg 2005;63:20-24